Global Anti-Inflammatory Therapeutics Market Overview
Anti-Inflammatory Therapeutics Market Size was valued at USD 102.5 Billion in 2023. The anti-inflammatory therapeutics market industry is projected to grow from USD 107.8 Billion in 2024 to USD 153.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.20% during the forecast period (2024 - 2032). Certain nutrients like omega-3 fatty acids, vitamin D, and antioxidants have been shown to possess anti-inflammatory properties while also supporting growth and development and are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Anti-Inflammatory Therapeutics Market Trends
-
The rising burden of chronic inflammatory diseases affects market growth
Market CAGR for the rising burden of chronic inflammatory diseases underscores the urgent need for effective anti-inflammatory therapeutics. Conditions such as rheumatoid arthritis, inflammatory bowel disease, and asthma are becoming increasingly prevalent worldwide, contributing to morbidity and mortality. Addressing this burden requires innovative approaches that target the underlying inflammatory mechanisms. Advancements in scientific understanding have paved the way for the development of novel anti-inflammatory drugs and therapies. Researchers have elucidated intricate pathways involved in inflammation, leading to the discovery of new therapeutic targets. For example, biologic drugs specifically target molecules involved in the inflammatory process, providing targeted relief with fewer side effects compared to traditional treatments.
Moreover, there is a growing emphasis on preventative care as a means to mitigate the impact of chronic inflammatory diseases. Healthcare systems are recognizing the importance of early intervention and lifestyle modifications in preventing the onset or progression of these conditions. Nutritional interventions, exercise programs, and stress management techniques are being incorporated into healthcare protocols to reduce inflammation and promote overall wellness. By prioritizing preventative measures, healthcare providers aim to reduce the reliance on pharmacological interventions and improve long-term health outcomes. This shift towards preventative care aligns with the holistic approach to healthcare, emphasizing the importance of addressing root causes rather than simply managing symptoms.
Additionally, a burgeoning emphasis on preventative care underscores its pivotal role in mitigating the impact of chronic inflammatory diseases. Healthcare systems are embracing the significance of early intervention and lifestyle modifications in forestalling the onset or progression of these ailments. Integrating nutritional interventions, tailored exercise regimens, and stress management strategies into healthcare paradigms aims to curtail inflammation and foster holistic well-being. By prioritizing preventative measures, healthcare practitioners aspire to diminish reliance on pharmacological remedies and bolster long-term health outcomes. This paradigm shift towards preventative care mirrors a holistic healthcare ethos, underscoring the imperative of addressing underlying causes rather than merely alleviating symptoms. Thus, driving the anti-inflammatory therapeutics market revenue.
Anti-Inflammatory Therapeutics Market Segment Insights
Anti-Inflammatory Therapeutics Drug Class Insights
The Anti-Inflammatory Therapeutics Market segmentation, based on Drug Class, includes Anti-inflammatory Biologics, NSAIDs, and Others. In 2023, the Anti-inflammatory Biologics segment dominated the market. The range of applications for anti-inflammatory biologics continues to expand beyond traditional conditions like rheumatoid arthritis. Biologic drugs are increasingly being used to treat a variety of inflammatory diseases such as psoriasis, inflammatory bowel disease, and ankylosing spondylitis, broadening their market reach.
Anti-Inflammatory Therapeutics Application Insights
The Anti-Inflammatory Therapeutics Market segmentation, based on Application, includes Auto-immune Diseases, Respiratory Conditions, and Others. In 2023, the Respiratory Conditions category generated the most income. The respiratory category has seen the introduction of new and improved treatment options, including biologic therapies, targeted drugs, and gene therapies. These advancements offer patients more personalized and effective treatment strategies, leading to increased adoption and revenue generation.
Figure 1: Anti-Inflammatory Therapeutics Market, by Application, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Anti-Inflammatory Therapeutics Route Of Administration Insights
The Anti-Inflammatory Therapeutics Market segmentation, based on Route of Administration, includes Oral, Injection, Topical, and Inhalation. In 2023, Oral generated the most income. Increasing awareness about the importance of oral health, both for dental hygiene and overall well-being has driven greater demand for oral healthcare products and services. Public health campaigns, educational initiatives, and dental professionals' advocacy have contributed to this heightened awareness, leading to more frequent dental visits and increased consumption of oral care products.
Anti-Inflammatory Therapeutics Distribution Channel Insights
The Anti-Inflammatory Therapeutics Market segmentation, based on Distribution Channel, includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. In 2023, the Hospital Pharmacies category generated the most income. The growing prevalence of complex and chronic diseases necessitates access to specialized medications and therapies, many of which are dispensed through hospital pharmacies. These medications often require specialized handling, monitoring, and administration, making hospital pharmacies the preferred distribution channel for such drugs.
Anti-Inflammatory Therapeutics Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American anti-inflammatory therapeutics market area will dominate this market. North America has a significant burden of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and asthma. Factors such as an aging population, sedentary lifestyles, and dietary habits contribute to the high prevalence of these conditions, driving demand for anti-inflammatory therapeutics.
Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Anti-Inflammatory Therapeutics Market By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe anti-inflammatory therapeutics market accounts for the second-largest market share. Europe faces a significant burden of chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. The aging population, sedentary lifestyles, and genetic predispositions contribute to the prevalence of these conditions, driving demand for anti-inflammatory therapeutics. Further, the German anti-inflammatory therapeutics market held the largest market share, and the UK anti-inflammatory therapeutics market was the fastest growing market in the European region.
The Asia-Pacific anti-inflammatory therapeutics Market is expected to grow at the fastest CAGR from 2024 to 2032. The prevalence of chronic diseases such as diabetes, obesity, and cardiovascular diseases is rising rapidly in the Asia-Pacific region due to urbanization, lifestyle changes, and dietary shifts. Chronic diseases often involve inflammation as a key pathological mechanism, leading to increased demand for anti-inflammatory therapeutics. Moreover, China’s anti-inflammatory therapeutics market held the largest market share, and the Indian anti-inflammatory therapeutics market was the fastest growing market in the Asia-Pacific region.
Anti-Inflammatory Therapeutics Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their service lines, which will help the anti-inflammatory therapeutics market grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new service launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the anti-inflammatory therapeutics industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global anti-inflammatory therapeutics industry to benefit clients and increase the market sector. In recent years, the anti-inflammatory therapeutics industry has offered some of the most significant advantages to medicine. Major players in the anti-inflammatory therapeutics market, including AbbVie, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Pfizer, Inc., Novartis AG, GlaxoSmithKline plc., Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Sanofi, and others, are attempting to increase market demand by investing in research and development operations.
AbbVie is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines in areas of high unmet medical need. Established in 2013 as a spin-off from Abbott Laboratories, AbbVie has quickly established itself as a leader in the pharmaceutical industry. The company focuses on several therapeutic areas, including immunology, oncology, neuroscience, and virology. AbbVie's flagship product, Humira, is one of the world's best-selling drugs and is widely used to treat autoimmune diseases such as rheumatoid arthritis and psoriasis. With a commitment to advancing science and improving patient outcomes, AbbVie continues to invest in research and development to bring transformative therapies to patients around the globe.
Merck & Co., known as MSD, outside of the United States and Canada, is a global healthcare company that operates in more than 140 countries. Founded in 1891, Merck is one of the largest pharmaceutical companies in the world, with a diverse portfolio of prescription medicines, vaccines, biologic therapies, and animal health products. The company's focus areas include oncology, vaccines, infectious diseases, cardiovascular diseases, and diabetes. Merck is renowned for its innovative research and development efforts, leading to the discovery of groundbreaking therapies such as Keytruda, an immuno-oncology drug used to treat various types of cancer. Committed to improving health and well-being worldwide, Merck collaborates with partners across the healthcare ecosystem to address unmet medical needs and advance the science of medicine.
Key Companies in the anti-inflammatory therapeutics market include
- AbbVie, Inc.
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Pfizer, Inc.
- Novartis AG
- GlaxoSmithKline plc.
- Amgen, Inc.
- Hoffmann-La Roche Ltd.
- AstraZeneca
- Sanofi
Anti-Inflammatory Therapeutics Industry Developments
July 2023: AbbVie, Inc. announced that the first patient was dosed in the phase 3 Step-Up HS study evaluating upadacitinib (RINVOQ) in adults and adolescents with moderate to severe hidradenitis suppurativa (HS) who have failed anti-tumor necrosis factor (TNF) therapy and/or one approved non-anti-TNF inhibitor therapy for HS.
March 2023: Pfizer, Inc. announced the completion of its acquisition of Arena Pharmaceuticals, a clinical-stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases
May 2023: AbbVie, Inc. announced that the U.S. Food and Drug Administration (FDA) approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more TNF blockers.
Anti-Inflammatory Therapeutics Market Segmentation
Anti-Inflammatory Therapeutics Drug Class Outlook
- Anti-inflammatory Biologics
- NSAIDs
- Others
Anti-Inflammatory Therapeutics Application Outlook
- Auto-immune Diseases
- Rheumatoid Arthritis
- Psoriasis
- Multiple Sclerosis
- Crohn's Disease
- Ulcerative Colitis
- Others
- Respiratory Conditions
- Others
Anti-Inflammatory Therapeutics Route of Administration Outlook
- Oral
- Injection
- Topical
- Inhalation
Anti-Inflammatory Therapeutics Distribution Channel Outlook
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Anti-Inflammatory Therapeutics Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric
|
Details
|
|
Market Size 2023
|
USD 102.5 Billion
|
|
Market Size 2024
|
USD 107.8 Billion
|
|
Market Size 2032
|
USD 153.7 Billion
|
|
Compound Annual Growth Rate (CAGR)
|
5.20% (2024-2032)
|
|
Base Year
|
2023
|
|
Market Forecast Period
|
2024-2032
|
|
Historical Data
|
2019- 2022
|
|
Market Forecast Units
|
Value (USD Billion)
|
|
Report Coverage
|
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
|
|
Segments Covered
|
Drug Class, Application, Route of Administration, Distribution Channel, and Region
|
|
Geographies Covered
|
North America, Europe, Asia Pacific, and the Rest of the World
|
|
Countries Covered
|
The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea
|
|
Key Companies Profiled
|
AbbVie, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Pfizer, Inc., Novartis AG, GlaxoSmithKline plc., Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Sanofi
|
|
Key Market Opportunities
|
·      The shift towards preventing chronic diseases is increasing interest in using anti-inflammatory drugs for early intervention and risk reduction strategies.
|
|
Key Market Dynamics
|
·      The rising burden of chronic inflammatory diseases
|
Frequently Asked Questions (FAQ) :
The Anti-Inflammatory Therapeutics Market size was valued at USD 107.8 Billion in 2024.
The global market is projected to grow at a CAGR of 5.20% during the forecast period, 2024-2032.
North America had the largest share in the global market.
The key players in the market are AbbVie, Inc., Merck & Co., Inc., Johnson & Johnson Services, Inc., Pfizer, Inc., Novartis AG, GlaxoSmithKline plc., Amgen, Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Sanofi, and others.
The Anti-inflammatory Biologics category dominated the market in 2023.
Respiratory Conditions had the largest share of the global market.
